Menée par enquête dans 5 pays européens (France, Allemagne, Italie, Espagne, Royaume-Uni) auprès de 881 médecins soignant 17 193 patients atteints de tumeurs solides ou hématologiques, cette étude analyse l'utilisation de bisphosphonates pour la prise en charge des lésions ou métastases osseuses

The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies – a European survey

Lebret, T. ; Casas, A. ; Cavo, M. ; Woll, P. J. ; Deleplace, C. ; Kennedy, C. ; Schoen, P. ; Jackisch, C.

Bone metastases in patients with solid tumours (ST) and bone lesions in patients with haematological malignancies (HM) are common. Associated skeletal-related events (SREs) cause severe pain, reduced quality of life and place a burden on health care resources. Bone-targeted agents can reduce the risk of SREs. We evaluated the management of bone metastasis/lesions in five European countries (France, Germany, Italy, Spain and the UK) by an observational chart audit. In total, 881 physicians [...]

Menée à partir de données portant sur 7 105 patients ayant survécu à un cancer pédiatrique et sur 372 frères et soeurs de patients, cette étude analyse, à l'aide d'un système de score et par rapport à la population générale (échantillon de 12 803 personnes), la qualité de vie à long terme des patients en fonction du nombre et de la gravité des affections chroniques consécutives aux traitements

Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors

Yeh, Jennifer M. ; Hanmer, Janel ; Ward, Zachary J. ; Leisenring, Wendy M. ; Armstrong, Gregory T. ; Hudson, Melissa M. ; Stovall, Marilyn ; Robison, Leslie L. ; Oeffinger, Kevin C. ; Diller, Lisa

Health utility, a summary measure of quality of life, has not been previously used to compare outcomes among childhood cancer survivors and individuals without a cancer history. We estimated health utility (0, death; 1, perfect health) using the Short Form-6D (SF-6D) in survivors (n = 7105) and siblings of survivors (n = 372) (using the Childhood Cancer Survivor Study cohort) and the general population (n = 12 803) (using the Medical Expenditures Panel Survey). Survivors had statistically [...]

Menée à partir des données 2002-2012 de registres suédois portant sur 984 patients atteints d'une leucémie myéloïde chronique (durée de suivi : 45 000 personnes-années), cette étude met en évidence, chez ces patients, des antécédents de tumeurs malignes et de maladies auto-immunes

Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia

Gunnarsson, N. ; Hoglund, M. ; Stenke, L. ; Wallberg-Jonsson, S. ; Sandin, F. ; Bjorkholm, M. ; Dreimane, A. ; Lambe, M. ; Markevarn, B. ; Olsson-Stromberg, U. ; Wadenvik, H. ; Richter, J. ; Sjalander, A.

We recently reported an increased incidence of second malignancies in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI). To elucidate whether this increase may be linked, not to TKI but rather to a hereditary or acquired susceptibility to develop cancer, we estimated the prevalence of malignancies, autoimmune disease (AD) and chronic inflammatory disease (CID) in CML patients prior to their CML diagnosis. Nationwide population-based registers were used to [...]

Menée au Royaume-Uni à partir de données portant sur 5 231 patients présentant une néoplasie myéloïde et issus d'un échantillon représentatif de la population britannique (âge médian au diagnostic : 72,4 ans ; durée de suivi : entre 2 et 11 ans), cette étude évalue, en fonction du sexe et de l'âge au diagnostic, l'incidence de différents types de néoplasies myéloïdes, les taux de survie relative et de survie globale à 5 ans ainsi que la proportion de syndromes myélodysplasiques ayant évolué vers une leucémie myéloïde aiguë

Myeloid malignancies in the real-world : Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15

Roman, Eve ; Smith, Alex ; Appleton, Simon ; Crouch, Simon ; Kelly, Richard ; Kinsey, Sally ; Cargo, Catherine ; Patmore, Russell

Background : Population-based information on cancer incidence, prevalence and outcome are required to inform clinical practice and research; but contemporary data are lacking for many myeloid malignancy subtypes. Methods : Set within a socio-demographically representative UK population of 4 million, myeloid malignancy data (N = 5231 diagnoses) are from an established patient cohort. Information on incidence, survival (relative & overall), transformation/progression, and prevalence is presented [...]

A partir de données portant sur 1 560 patients atteints d'un cancer de la prostate et de données issues d'études d'association sur le génome entier, cette étude évalue l'effet de 75 variants génétiques associés au risque de cancer sur l'augmentation du risque de toxicité liée à une radiothérapie

Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity

Ahmed, Mahbubl ; Dorling, Leila ; Kerns, Sarah ; Fachal, Laura ; Elliott, Rebecca ; Partliament, Matt ; Rosenstein, Barry S. ; Vega, Ana ; Gomez-Caamano, Antonio ; Barnett, Gill ; Dearnaley, David P. ; Hall, Emma ; Sydes, Matt ; Burnet, Neil ; Pharoah, Paul D. P. ; Eeles, Ros ; West, Catharine M. L.

Background: Numerous germline single-nucleotide polymorphisms increase susceptibility to prostate cancer, some lying near genes involved in cellular radiation response. This study investigated whether prostate cancer patients with a high genetic risk have increased toxicity following radiotherapy. Methods: The study included 1560 prostate cancer patients from four radiotherapy cohorts: RAPPER (n=533), RADIOGEN (n=597), GenePARE (n=290) and CCI (n=150). Data from genome-wide association studies [...]

Menée à partir des données 1999-2010 de quatre Etats américains portant sur quelque 10 millions d'hommes âgés de 35 ans ou plus, cette étude analyse la corrélation entre l'évolution de la prévalence du tabagisme et l'évolution du taux de mortalité par cancer de la prostate

Cigarette Smoking and Prostate Cancer Mortality in Four US States, 1999-2010

Jones, Miranda R. ; Joshu, Corinne E. ; Kanarek, Norma ; Navas-Acien, Ana ; Richardson, Kelly A. ; Platz, Elizabeth A.

Introduction : In the United States, prostate cancer mortality rates have declined in recent decades. Cigarette smoking, a risk factor for prostate cancer death, has also declined. It is unknown whether declines in smoking prevalence produced detectable declines in prostate cancer mortality. We examined state prostate cancer mortality rates in relation to changes in cigarette smoking. Methods : We studied men aged 35 years or older from California, Kentucky, Maryland, and Utah. Data on state [...]

Menée aux Etats-Unis à partir de données portant sur 66 197 patients atteints d'un adénocarcinome du rectum de stade II ou III diagnostiqué entre 2004 et 2012, cette étude analyse l'évolution des stratégies thérapeutiques

Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base

Sineshaw, Helmneh M. ; Jemal, Ahmedin ; Thomas, Charles R. ; Mitin, Timur

BACKGROUND In the United States, neoadjuvant chemoradiotherapy (NACRT) is widely accepted as the standard of care in the treatment of patients with locally advanced rectal cancer. In the current study, the authors attempted to examine patterns of treatment in the United States over the past decade. METHODS Using the National Cancer Data Base, a total of 66,197 patients who were diagnosed with American Joint Committee on Cancer stage II to III rectal adenocarcinoma and treated between 2004 and [...]

A partir des données des registres américains des cancers et de la base Medicare portant sur des patientes atteintes d'un cancer du sein de stade I à III (âge supérieur à 65 ans), cette étude évalue l'association entre une hormonothérapie par inhibiteurs de l'aromatase ou par tamoxifène et le risque de diabète

Hormonal Therapy for Breast Cancer and Diabetes Incidence Among Postmenopausal Women

Santorelli, Melissa L. ; Hirshfield, Kim M. ; Steinberg, Michael B. ; Rhoads, George G. ; Lin, Yong ; Demissie, Kitaw

Purpose : The purpose of this study was to evaluate associations between hormonal therapy for breast cancer and subsequent diabetes incidence. Methods : The Surveillance, Epidemiology and End Results (SEER) – Medicare linked data was used. Stage I-III breast cancer patients diagnosed at 65+ years who filled at least two prescriptions for an aromatase inhibitor (AI) or tamoxifen by the end of 2008, and within 12 months of breast cancer diagnosis, were selected. Women without cancer from a 5% [...]

Menée en Ontario à partir de données portant sur 18 540 patientes atteintes d'un cancer du sein de stade I à III traité entre 2007 et 2012 et à partir de données portant sur un échantillon de 92 700 témoins (âge médian : 54 ans ; durée de suivi : 3 ans), cette étude évalue en pratique clinique le risque de cardiotoxicité en fonction du traitement systémique reçu

Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice : A Population-Based Cohort Study

Thavendiranathan, Paaladinesh ; Abdel-Qadir, Husam ; Fischer, Hadas D. ; Camacho, Ximena ; Amir, Eitan ; Austin, Peter C. ; Lee, Douglas S.

Purpose : Most women diagnosed with breast cancer are younger than 65 years of age. Population-based studies on cancer therapy–related cardiotoxicity have focused on older women. We sought to determine the risk of cardiotoxicity with breast cancer therapy in women with an age distribution representative of routine clinical practice. Methods : This was a population-based retrospective cohort study including 14 regional cancer centers in Ontario, Canada. Adult women receiving chemotherapy for [...]

Menée à partir des données des registres néerlandais des cancers sur la période 1991-2010, cette étude analyse l'évolution de l'incidence des cancers de la cavité buccale, du taux de mortalité, de la survie ainsi que les tendances en matière de traitements

Trends in oral cavity cancer incidence, mortality, survival and treatment in the Netherlands

van Dijk, Boukje A. C. ; Brands, Marieke T. ; Geurts, Sandra M. E. ; Merkx, Matthias A. W. ; Roodenburg, Jan L. N.

Information on epidemiology is essential to evaluate care for the growing group of oral cancer patients. We investigated trends in incidence, mortality and relative survival rates for oral cavity cancer (OCC) and its subsites in the Netherlands from 1991 to 2010, and relate these to changes in stage and treatment. Patient (age, sex), tumour (subsite, stage) and treatment characteristics of patients diagnosed with OCC (ICD-O-3: C02-C06) in 1991–2010 were extracted from the Netherlands Cancer [...]

Menée en Angleterre à partir de données portant sur 275 985 patients atteints d'un cancer colorectal, 359 771 patientes atteintes d'un cancer du sein, 286 426 patients atteints d'un cancer de la prostate et 283 940 patients atteints d'un cancer du poumon (diagnostics entre 2001 et 2010), cette étude de cohorte rétrospective analyse les coûts des soins en fonction du stade au diagnostic et de l'âge des patients

Cost of care for cancer patients in England: evidence from population-based patient-level data

Laudicella, Mauro ; Walsh, Brendan ; Burns, Elaine ; Smith, Peter C.

Background: Health systems are facing the challenge of providing care to an increasing population of patients with cancer. However, evidence on costs is limited due to the lack of large longitudinal databases. Methods: We matched cost of care data to population-based, patient-level data on cancer patients in England. We conducted a retrospective cohort study including all patients age 18 and over with a diagnosis of colorectal (275 985 patients), breast (359 771), prostate (286 426) and lung [...]

Menée au Royaume-Uni à partir des données d'un grand centre hospitalier universitaire portant sur 3 274 patients atteints d'un cancer du poumon, cette étude identifie les facteurs affectant le coût des soins secondaires

Factors affecting hospital costs in lung cancer patients in the United Kingdom

Kennedy, Martyn P. T. ; Hall, Peter S. ; Callister, Matthew E. J.

Introduction : Rising healthcare costs and financial constraints are increasing pressure on healthcare budgets. There is little published data on the healthcare costs of lung cancer in the UK, with international studies mostly small and limited by data collection methods. Accurate assessment of healthcare costs is essential for effective service planning. Methods : We conducted a retrospective, descriptive cohort study linking clinical data from a local electronic database of lung cancer [...]

Menée en Allemagne auprès de 17 oncologues, cette étude qualitative analyse leurs expériences relatives aux discussions sur les médecines complémentaires et alternatives avec leurs patients atteints de cancer

Oncologists’ experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis

Corina, Güthlin ; Christine, Holmberg ; Klein, Gudrun

Purpose : The rising use of complementary and alternative medicine (CAM) means oncologists are increasingly asked by patients to discuss CAM treatment options. However, no formal training or established standards are available on the subject. The aim of this paper was to investigate real-world discussions of CAM treatments. In particular, we wanted to learn about the values, norms and defining features that characterise oncologist-patient discussions on CAM. Methods : Semi-standardised [...]